Discrediting microscopic pyuria and leucocyte esterase as diagnostic surrogates for infection in patients with lower urinary tract symptoms: results from a clinical and laboratory evaluation

被引:39
|
作者
Kupelian, Anthony S. [1 ]
Horsley, Harry [1 ]
Khasriya, Rajvinder [1 ]
Amussah, Rasheedah T. [2 ]
Badiani, Raj [2 ]
Courtney, Angela M. [2 ]
Chandhyoke, Nihil S. [2 ]
Riaz, Usama [3 ]
Savlani, Karishma [2 ]
Moledina, Malik [4 ]
Montes, Samantha [2 ]
O'Connor, Dominic [2 ]
Visavadia, Rakhee [2 ]
Kelsey, Michael [5 ]
Rohn, Jennifer L. [1 ]
Malone-Lee, James [1 ]
机构
[1] UCL, Dept Med, Res Dept Clin Physiol, London N19 5LW, England
[2] UCL, UCL Med Sch, London N19 5LW, England
[3] UCL, Dept Physiol, London N19 5LW, England
[4] Imperial Coll Sch Med, London, England
[5] Whittington Hlth NHS, Whittington Hosp, Dept Microbiol, London, England
关键词
microscopic pyuria; lower urinary tract symptoms; urinary tract infection; DIPSTICK TESTS; WOMEN; BACTERIA; SEDIMENT;
D O I
10.1111/j.1464-410X.2012.11694.x
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
What's known on the subject? and What does the study add? Microscopic pyuria is widely used as a surrogate marker of infection, although there is little data supporting its use in patients who present with non-acute LUTS. The effects of urinary storage, preservation, and the use of laboratory methods to enhance leucocyte detection, are also unclear. This large, prospective study highlights the poor performance of dipstick urine analysis, and direct microscopy, as surrogate markers of UTI in patients with LUTS. A series of laboratory analyses also examine the effects of urine handling and processing on test integrity, which have important implications for clinical practice. Objective To evaluate the diagnostic performance of pyuria as a surrogate marker of urinary tract infection (UTI) in patients with chronic lower urinary tract symptoms (LUTS), and determine the impact of sample storage, cytocentrifugation, and staining techniques, on test performance. Patients and Methods Between 2008 and 2011, we recruited 1223 patients (120 men; 1103 women; mean age 54 years) with one or more LUTS from a specialist urological outpatient service. We conducted a prospective observational study to determine the performance of microscopic pyuria 10wbc/L as a surrogate marker of UTI in patients with LUTS. All patients provided clean-catch midstream urine (MSU) samples for analysis, and routine microbiological cultures were used as our reference standard. We also scrutinised the performance of dipstick leucocyte esterase trace' in the detection of microscopic pyuria. The influence of sample handling and processing on test performance was examined in a series of laboratory studies. The effects of storage on leucocyte decay were determined using repeated microscopic assessments of individual urine samples, to plot temporal changes in leucocyte numbers. This study used varied storage conditions (approximate to 20 degrees C and 4 degrees C), and boric acid preservation. Paired microscopic assessments were used to determine the effects of centrifugation on leucocyte salvage in spun/unspun samples (relative centrifugal force range 39-157g). Similar methods were used to assess microscopic leucocyte quantification in stained/unstained urine (Sternheimer-Malbin protocol). Results The positive predictive value (PPV) and negative predictive value (NPV) of pyuria as a surrogate marker of UTI were 0.40 (95% confidence interval [CI] 0.37-0.43) and 0.75 (95% CI 0.73-0.76), respectively. The dipstick was unable to identify significant microscopic pyuria (10wbc/L) in 60% of the samples: PPV 0.51 (95% CI 0.48-0.55); NPV 0.75 (95% CI 0.73-0.76). Microscopic pyuria performed poorly as a surrogate of UTI defined by bacterial culture. Whilst refrigeration and preservation did retard leucocyte loss (F = 11; DF = 2; P < 0.001), 40% of cells were still lost by 4h. Centrifugation had an unpredictable influence on cell salvage (coefficient of variation 5750%) and the use of staining to improve leucocyte detection proved ineffective (Z = -0.356; P = 0.72). Conclusions Pyuria performs badly as a surrogate of UTI in patients with LUTS. This is exacerbated by cell loss during storage, and neither centrifugation, nor staining, appears to confer any diagnostic advantage. Clinicians should be alerted to the significant limitations of these tests.
引用
收藏
页码:231 / 238
页数:8
相关论文
共 38 条
  • [1] Is obstruction predictable by clinical evaluation in patients with lower urinary tract symptoms?
    Madersbacher, S
    Klingler, HC
    Djavan, B
    Stulnig, T
    Schatzl, G
    Schmidbauer, CP
    Marberger, M
    BRITISH JOURNAL OF UROLOGY, 1997, 80 (01): : 72 - 77
  • [2] Clinical evaluation of tamsulosin in the relief of lower urinary tract symptoms in advanced prostate cancer patients
    Zhang, Tong
    Wu, Haihu
    Liu, Shuai
    He, Wei
    Ding, Kejia
    INTERNATIONAL UROLOGY AND NEPHROLOGY, 2017, 49 (07) : 1111 - 1117
  • [3] Clinical evaluation of tamsulosin in the relief of lower urinary tract symptoms in advanced prostate cancer patients
    Tong Zhang
    Haihu Wu
    Shuai Liu
    Wei He
    Kejia Ding
    International Urology and Nephrology, 2017, 49 : 1111 - 1117
  • [4] Chronic sacral neuromodulation in patients with lower urinary tract symptoms: Results from a national register
    Spinelli, M
    Bertapelle, P
    Cappellano, F
    Zanollo, A
    Carone, R
    Catanzaro, F
    Giardiello, G
    De Seta, F
    JOURNAL OF UROLOGY, 2001, 166 (02): : 541 - 545
  • [5] LOWER URINARY TRACT SYMPTOMS PREVALENCE IN SYSTEMIC SCLEROSIS PATIENTS: RESULTS FROM A COMPREHENSIVE ANALYSIS
    Pacini, Greta
    Trombetta, Amelia Chiara
    Goegan, Federica
    Paolino, Sabrina
    Pizzorni, Carmen
    Alessandri, Elisa
    Patane, Massimo
    Gotelli, Emanuele
    Ferrari, Giorgia
    Cattelan, Francesco
    Ghio, Massimo
    Casabella, Andrea
    Smith, Vanessa
    Cutolo, Maurizio
    ANNALS OF THE RHEUMATIC DISEASES, 2019, 78 : 852 - 853
  • [6] LOWER URINARY TRACT SYMPTOMS AND URINARY COMPLICATIONS IN PATIENTS WITH MULTIPLE SCLEROSIS: EVALUATION IN A CONTEMPORARY COHORT FROM A REFERRAL CENTER
    Sacco, E.
    Sebastianelli, A.
    Batocchi, A.
    Marti, A.
    Totaro, A.
    Tienforti, D.
    Cappa, E.
    D'Agostino, D.
    D'Onofrio, A.
    Vittori, M.
    Bassi, P.
    EUROPEAN UROLOGY SUPPLEMENTS, 2011, 10 (02) : 188 - 189
  • [7] Evaluation of the clinical pharmacist role in improving clinical outcomes in patients with lower urinary tract symptoms due to benign prostatic hyperplasia
    Mera Ababneh
    Duaa Shamieh
    Saddam Al Demour
    Abeer Rababa’h
    International Journal of Clinical Pharmacy, 2019, 41 : 1373 - 1378
  • [8] Evaluation of the clinical pharmacist role in improving clinical outcomes in patients with lower urinary tract symptoms due to benign prostatic hyperplasia
    Ababneh, Mera
    Shamieh, Duaa
    Al Demour, Saddam
    Rababa'h, Abeer
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACY, 2019, 41 (05) : 1373 - 1378
  • [9] CLINICAL AND URODYNAMIC RESULTS OF ALPHA BLOCKER DRUG TREATMENT IN PATIENTS WITH LOWER URINARY TRACT SYMPTOMS AND BENIGN PROSTATIC HYPERPLASIA
    Salinas, J.
    ARCHIVOS ESPANOLES DE UROLOGIA, 2015, 68 (02): : 161 - 171
  • [10] Urodynamic findings in amyotrophic lateral sclerosis patients with lower urinary tract symptoms: Results from a pilot study
    Arlandis, Salvador
    Francisco Vazquez-Costa, Juan
    Martinez-Cuenca, Esther
    Sevilla, Teresa
    Boronat, Francisco
    Broseta, Enrique
    NEUROUROLOGY AND URODYNAMICS, 2017, 36 (03) : 626 - 631